SCHEMBL4014358

SCHEMBL4014358

O=C(O)c1ccc(CNC(=O)c2cc(Cl)ccc2OCCc2ccc(Cl)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 3/20 0.67
PTGER2 P43116 2/20 0.54
NR1H4 Q96RI1 1/20 0.49
EPHX2 P34913 1/20 0.49
ALDH1A1 P00352 3/20 0.49
AKR1C3 P42330 1/20 0.48
AKR1B1 P15121 2/20 0.48
KMT2A Q03164 1/20 0.48
LMNA P02545 1/20 0.48
MRGPRX4 Q96LA9 1/20 0.48
PPARA Q07869 1/20 0.47
DNMT3A Q9Y6K1 1/20 0.47
HPGD P15428 2/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014415 0.96 PTGER4 (0.64) PTGER4PTGER2NR1H4ALDH1A1AKR1C3
SCHEMBL4013417 0.95 PTGER4 (0.76) PTGER4PTGER2NR1H4EPHX2AKR1C3
SCHEMBL2242766 0.88 PTGER4 (0.66) PTGER4PTGER2NR1H4EPHX2ALDH1A1
SCHEMBL4014975 0.87 PTGER4 (0.60) PTGER4PTGER2NR1H4EPHX2ALDH1A1
SCHEMBL692054 0.86 PTGER4 (0.58) PTGER4PTGER2NR1H4ALDH1A1AKR1C3
SCHEMBL1154066 0.84 AKR1C3 (0.55) PTGER4AKR1C3KMT2ALMNADNMT3A
SCHEMBL11464602 0.83 PTGER4 (0.69) PTGER4PTGER2NR1H4EPHX2ALDH1A1
SCHEMBL27653404 0.82 PTGER4 (0.69) PTGER4PTGER2NR1H4ALDH1A1KMT2A
SCHEMBL10180681 0.82 PTGER4 (0.73) PTGER4PTGER2ALDH1A1AKR1C3KMT2A
SCHEMBL13770803 0.81 PTGER4 (0.66) PTGER4PTGER2NR1H4EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756043-B1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS RAQUALIA PHARMA INC (JP) 2009-07-01 EP disclosed
EP-1756043-B1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS RAQUALIA PHARMA INC (JP) 2009-07-01 EP disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
US-20050250818-A1 Ortho substituted aryl or heteroaryl amide compounds PFIZER INC 2005-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250818-A1 Ortho substituted aryl or heteroaryl amide compounds OPRL1, PTGER1, OPRM1 PTGER4 19/4885PTGER2 6/4885NR1H4 191/4885
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PTGER4, PTGER2, OPRL1 PTGER4 1/4885PTGER2 2/4885NR1H4 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.